Form 4: CONMED Corp Director Mark Kaye Reports Acquisition of Stock Options and Restricted Stock Units

Director Mark Kaye reports acquisition of stock options and restricted stock units in CONMED Corp.

Summary

• On February 24, 2025, Mark Kaye, a director of CONMED Corp, reported the acquisition of 1,846 stock options and 152 restricted stock units (RSUs).
• The stock options have an exercise price of $61.97 and vest 100% after one year, expiring on February 24, 2035.
• Each RSU represents a contingent right to receive one share of CONMED Corp common stock and also vests 100% after one year, expiring on February 24, 2035.
• Kaye directly owns 1,846 derivative securities and 152 shares of common stock following the reported transactions.
• A Limited Power of Attorney was executed on February 24, 2025, granting authority to several individuals at CONMED Corporation to act on Kaye's behalf for Section 16 and Rule 144 filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options and RSUs granted to a director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock options and RSUs by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The granting of stock options and RSUs is a common practice to align the interests of directors with those of shareholders.

Stakeholder Impact

• The granting of stock options and RSUs to a director can align their interests with those of shareholders, potentially incentivizing them to make decisions that increase shareholder value.

Key Dates